Oxford Biomedica Regulatory News (OXB)

7 Aug 2007 07:00

Oxford Biomedica PLC07 August 2007 For immediate release 7 August 2007 OXFORD BIOMEDICA NOTICE OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2007 Date: 11 September 2007 Oxford, UK - 7 August 2007: Oxford BioMedica (LSE: OXB), a leading gene therapycompany, announces that it will be releasing its interim results for the sixmonths ended 30 June 2007 on Tuesday 11 September. Analyst Briefing: An analyst briefing will be held at 10:00 am on 11 September at the offices ofBuchanan Communications, 45 Moorfields, London EC2. Web cast: Simultaneously to the analyst briefing at 10.00 am, there will be a live audioweb cast of the results presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the start of the briefing. This will also be available for replay shortly after thepresentation. -Ends- For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 783 000Professor Alan Kingsman, Chief Executive City/Financial Enquiries: Tel: +44 (0)20 7466 5000Lisa Baderoon/Mary-Jane Johnson Buchanan Communications Scientific/Trade Press Enquiries: Tel: +44 (0)20 7886 8150Katja Stout/ Susan Yu/ Gemma BradleyNorthbank Communications Notes for editors About Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment and commercialisation of novel therapeutic vaccines and gene-basedtherapies with a focus on oncology and neurotherapy. The Company was establishedin 1995 as a spin-out from Oxford University, and is listed on the London StockExchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. In oncology, the lead product candidateis TroVax(R), an immunotherapy for multiple solid cancers, which is licensed tosanofi-aventis for global development and commercialisation. A Phase III trialof TroVax in renal cancer is ongoing and sanofi-aventis is implementing adevelopment plan for colorectal cancer. Oxford BioMedica's oncology pipelineincludes a specific immunotherapy candidate, Hi-8(R) MEL, for melanoma, whichhas completed two clinical trials. In neurotherapy, the Company's lead product,ProSavin(R), is expected to enter clinical development for Parkinson's diseasein 2007. The neurotherapy pipeline also includes preclinical gene-basedtherapeutics for vision loss, motor neuron disease and nerve repair. The Company is underpinned by over 80 patent families, which represent one ofthe broadest patent estates in the field. The Company has a staff ofapproximately 80 split between its main facilities in Oxford and its whollyowned subsidiary, BioMedica Inc, in San Diego, California. Corporate partnersinclude sanofi-aventis for TroVax and Wyeth for the targeted antibody therapy.The Company also has collaborations with Sigma-Aldrich, MolMed and Virxsys.Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline andPfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock Exchange